Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Plunkett Research, Ltd.
$99.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AstraZeneca PLC Launches Zinforo


Thursday, 6 Dec 2012 09:27am EST 

AstraZeneca PLC announced that it has launched Zinforo (ceftarolinfosamil), a new antibiotic for the treatment of adult patients with complicated skin and soft tissue infections or with community-acquired pneumonia. Zinforo has been developed with the goal to deviate from the already approved cephalosporins, and has a bactericidal activity against a spectrum of common infection-causing bacteria, such as Staphylococcus aureus, including MRSA. MRSA is mainly spread within and between care facilities, and has become one of the main healthcare hygiene problems worldwide. Serious MRSA infections are so far rare in the Nordic countries, but they have seen a steady increase in Sweden and Denmark since MRSA became notifiable in Sweden under Diseases Act in 2000. Zinforo has also shown clinical efficacy in sensitive populations, such as elderly patients or patients with underlying diseases (such as diabetes or peripheral vascular disease in complicated infections of skin and soft tissue, and chronic obstructive pulmonary disease (COPD) or asthma at community-acquired pneumonia). This can help overcome the difficulty that has existed in the treatment of this patient population, which needs an antibiotic that is both efficient and has good tolerability. 

Company Quote

4421.0
-5.0 -0.11%
23 Jul 2014